171 related articles for article (PubMed ID: 10638980)
1. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer.
Phillips HA; Howard GC; Miller WR
Br J Cancer; 2000 Jan; 82(1):136-41. PubMed ID: 10638980
[TBL] [Abstract][Full Text] [Related]
2. Frequent association of p53 gene mutation in invasive bladder cancer.
Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
[TBL] [Abstract][Full Text] [Related]
3. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in urinary bladder cancer.
Berggren P; Steineck G; Adolfsson J; Hansson J; Jansson O; Larsson P; Sandstedt B; Wijkström H; Hemminki K
Br J Cancer; 2001 Jun; 84(11):1505-11. PubMed ID: 11384101
[TBL] [Abstract][Full Text] [Related]
6. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors.
Soong R; Iacopetta BJ
Mod Pathol; 1997 Mar; 10(3):252-8. PubMed ID: 9071734
[TBL] [Abstract][Full Text] [Related]
7. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
8. Detection of p53 gene mutations in sputum samples and their implications in the early diagnosis of lung cancer in suspicious patients.
Wang B; Li L; Yao L; Liu L; Zhu Y
Chin Med J (Engl); 2001 Jul; 114(7):694-7. PubMed ID: 11780329
[TBL] [Abstract][Full Text] [Related]
9. A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos.
Kannio A; Ridanpää M; Koskinen H; Partanen T; Anttila S; Collan Y; Hietanen E; Vainio H; Husgafvel-Pursiainen K
Cancer Epidemiol Biomarkers Prev; 1996 Jan; 5(1):33-9. PubMed ID: 8770464
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.
Vet JA; Witjes JA; Marras SA; Hessels D; van der Poel HG; Debruyne FM; Schalken JA
Clin Cancer Res; 1996 Jun; 2(6):1055-61. PubMed ID: 9816267
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
13. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of p53 gene mutation in esophageal exfoliative cells].
Kou YL; Zhang JR; Zhou Q; Zhao YF; Chen GD
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):349-52. PubMed ID: 15312345
[TBL] [Abstract][Full Text] [Related]
15. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
16. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
17. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
19. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
[TBL] [Abstract][Full Text] [Related]
20. Analyses of p53 gene mutations in primary human bladder cancer.
Miyamoto H; Kubota Y; Shuin T; Torigoe S; Hosaka M; Iwasaki Y; Danenberg K; Danenberg PV
Oncol Res; 1993; 5(6-7):245-9. PubMed ID: 8123944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
